Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection
1. BHVN stock dropped 36.63%, nearing its 52-week low. 2. FDA issued a Complete Response Letter rejecting Vyglxia's NDA. 3. Analysts express concerns about funding the prioritized pipeline. 4. Biohaven is restructuring, cutting R&D expenses by 60%. 5. William Blair downgraded Biohaven from Outperform to Market Perform.